We are a life science-start-up that set out as a spin-off from SciLifeLab/Karolinska Institutet. Based on our work on microbial metadegradomics  we aim to increase  efficiency, safety and speed in the development of small molecules modulating the microbiome. Our technology provides  immediate information of the effect of new drug substances on the microbiome.

Currently, our team focus on the application of this technology to measure cellular growth at the molecular level and to speed up the diagnosis of phenotypic antimicrobial resistance .

OUR MISSION
The rapid emergence of antibiotic-resistant bacteria and multidrug-resistant pathogenic fungi pose a threat to global health. If no urgent actions are taken, by 2050, antimicrobial resistance (AMR) will cause an estimated loss of 10 million lives and $US100 trillion. Fast and accurate diagnosis of antimicrobial resistant strains is key to contain the rise of AMR, limit its spread and provide adequate treatment to patients.

At 3N Bio we work on the development quick and simple tests able to detect antimicrobial resistance independent of the drug resistance mechanism used. We aim to provide fast diagnosis for bacterial infections and provide actionable recommendation for antibiotic usage. Our final goal is to  accelerate diagnosis,  improve patient survival, and contribute to individualized and rational use of antibiotics.

3N Bio

Susanne Huch

Vicent Pelechano

This department consists of top executives responsible for overseeing the overall direction and strategic vision of the organization.

3N Bio

Org chart

Teams

Executive Leadership

Offices

3N Bio

Org chart

Teams

Executive Leadership

Offices

Related companies